The objective of this project is to utilize different forms of a mouse monoclonal antibody, mMAG-1, not only to direct successful imaging of breast cancer but also to develop more rational approaches to treatment. The hypothesis being tested is that Glycopeptide-Related cell-Surface Antigen (GRSA) will provide a sensitive and reliable target for the detection and effective treatment of breast cancer by mMAG-1 and related antibodies. Our data shows GRSA expression is a feature common to all, or most, breast cancers and DCIS. I also shows GRSA-like antigens can be targeted in patients with antibodies, and that our MAG-1 monoAb not only recognizes GRSA in all of breast tumors but also targets GRSA in vitro. Preliminary findings also indicate MAG-1 and 90Yttrium-labeled MAG-1 can decrease growth of breast cancer xenografts in mice. Phase 1 goals are directed towards (i) performing and completing a 'proof of principle' to determine the usefulness of 99technetium-labeled Fab fragments of mouse monoclonal antibody (mMAG-1) to successfully image breast cancer tumor xenografts in nu/nu mice, and; (ii) performing and completing a 'proof of principle' determine if MAG-1 (mMAG-1) or 90Yttrium-labeled mMAG-1 can kill or significantly retard the growth of breast tumor xenografts in nu/nu mice. These investigations will employ, RT-PCR, ligation, and cloning, DNA sequencing, immunohistochemistry, antibody modification, Northern and Western analysis with densiometric quantitation, RIA, tumor-directed targeting, whole-body scintigraphy for 99mTechnetium, cytofluorographic and radiometric quantitation, radioligand binding, flow cytometry, and cell and tumor growth assessments. A successful end-point of our Phase 1 studies would be the clear determination that fragments of mMAG-1 can direct radioimaging, and both unlabeled and 90Yttrium-labeled mMAG-1 can kill tumor cells or significantly curtail their growth in vivo. The proposed research is expected to lead to new and successful therapeutic approaches for managing breast cancer. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA119483-01
Application #
7053487
Study Section
Special Emphasis Panel (ZRG1-SBMI-F (10))
Program Officer
Menkens, Anne E
Project Start
2006-09-28
Project End
2007-08-31
Budget Start
2006-09-28
Budget End
2007-08-31
Support Year
1
Fiscal Year
2006
Total Cost
$100,000
Indirect Cost
Name
Woomera Therapeutics, Inc.
Department
Type
DUNS #
149245123
City
Lebanon
State
NH
Country
United States
Zip Code
03766
North, William G; Pang, Roy H L; Gao, Guohong et al. (2011) Native MAG-1 antibody almost destroys human breast cancer xenografts. Breast Cancer Res Treat 127:631-7